GLSI at a glance
Greenwich LifeSciences, Inc. (GLSI, SEC CIK 1799788) filed its latest 10-K annual report on June 1, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on December 18, 2025 and Form 4 insider filings as recently as July 30, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 14 institutional investment managers tracked by SignalX reported holding Greenwich LifeSciences, Inc. (GLSI) shares worth $28.7 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Patel Snehal on July 29, 2026 of 700 shares at $13.10 per share.
- In the last 90 days, GLSI insiders reported 5 open-market purchases ($97K) and 0 open-market sales ($0) on Form 4, a net purchase of $97K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 5 buys · 0 sells
- Net +$97K
- 13F holders
- 14 funds
- $28.7M · −2 vs prior quarter
- Latest 10-Q
- Aug 11, 2026
- Quarterly report
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY; clinical-stage company with no commercialization
- R&D expense $3.56M, up 4% from $3.42M; clinical expenses primary driver
- G&A expense $463K, up 31% from $353K; employee, management, and board options grant
- Cash $8.88M vs $6.18M at December 31, 2025; operating cash use $6.64M vs $4.07M
- ATM financing net proceeds $9.34M; additional capital required for operations and clinical trials
Risk Factors
- No material changes from Form 10-K risk factors for year ended December 31, 2025
AI summary of the GLSI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
SignalX for GLSI
Don't miss the next GLSI filing
- Alerts as it files. A push when GLSI files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut GLSI, by share count.
- Ask anything. An AI agent that reads every GLSI filing and answers with sources.
GLSI alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Patel Snehal | Buy | Jul 29, 2026 | 700 | $13.10 |
| Patel Snehal | Buy | Jul 28, 2026 | 1,500 | $13.59 |
| Patel Snehal | Buy | Jul 27, 2026 | 1,500 | $13.62 |
| Patel Snehal | Buy | Jul 24, 2026 | 1,100 | $12.88 |
| Patel Snehal | Buy | Jul 23, 2026 | 2,500 | $13.14 |
| Patel Snehal | Buy | Jan 13, 2026 | 1,800 | $29.83 |
| Patel Snehal | Buy | Jan 12, 2026 | 2,900 | $27.54 |
| Patel Snehal | Buy | Dec 31, 2025 | 4,300 | $21.36 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Operating Income | -$9.3M | -$16.0M | -$19.4M | |
| Net Income | -$8.9M | -$15.8M | -$19.4M | |
| Balance Sheet | ||||
| Total Assets | $7.0M | $4.1M | $6.2M | |
| Equity | $6.7M | $2.5M | $353K | |
| ROE | -132.7% | -623.1% | -5480.5% | |
| Per Share | ||||
| EPS | $-0.69 | $-1.21 | $-1.43 | |
| Cash Flow | ||||
| Operating CF | -$6.5M | -$7.3M | -$9.9M | |
Source: XBRL data in Greenwich LifeSciences, Inc. (GLSI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate GLSI share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 14 | $28.7M |
| Q1 2026 | 16 | $27.7M |
| Q4 2025 | 14 | $19.6M |
| Q3 2025 | 16 | $9.3M |
| Q2 2025 | 16 | $8.5M |
| Q1 2025 | 11 | $4.7M |
| Q4 2024 | 7 | $5.3M |
| Q3 2024 | 6 | $2.9M |
- BlackRock+52.0K (+12%)
- Vanguard Portfolio Management LLC+21.9K (+37%)
- Morgan Stanley+13.6K (+46%)
- State Street Corp+9.2K (+7%)
- Northern Trust+5.1K (+7%)
- Vanguard Capital Management LLC−20.1K (-7%)
- Raymond James Financial−700 (-7%)
- Goldman Sachs Group−192 (-0%)
- FMR LLC (Fidelity)−111 (-3%)
- PNC Financial Services−5 (-50%)
- Millennium Management−17.4K
- U.S. Bancorp−15
Source: 13F-HR filings on SEC EDGAR (aggregated from 100 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
GLSI filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 29, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 10-Q | Jun 4, 2026 | Mar 31, 2026 | Analysis | |
| 10-K | Jun 1, 2026 | Dec 31, 2025 | - | |
| 4 | Jan 15, 2026 | - | - | |
| 4 | Jan 14, 2026 | - | - | |
| 4 | Jan 5, 2026 | - | - | |
| 4 | Jan 2, 2026 | - | - | |
| 4 | Dec 19, 2025 | - | - | |
| 8-K | Dec 18, 2025 | - | - | |
| 4 | Nov 28, 2025 | - | - | |
| 10-Q | Nov 14, 2025 | Sep 30, 2025 | Analysis | |
| 10-Q | Aug 14, 2025 | Jun 30, 2025 | - | |
| 10-Q | May 20, 2025 | Mar 31, 2025 | - | |
| 10-K | Apr 15, 2025 | Dec 31, 2024 | - | |
| 10-Q | Nov 14, 2024 | Sep 30, 2024 | - | |
| 10-Q | Aug 14, 2024 | Jun 30, 2024 | - | |
| 10-Q | May 20, 2024 | Mar 31, 2024 | - | |
| 10-K | Apr 15, 2024 | Dec 31, 2023 | - | |
| 10-Q | Oct 19, 2023 | Sep 30, 2023 | - | |
| 10-Q | Aug 21, 2023 | Jun 30, 2023 | - | |
| 10-Q | May 22, 2023 | Mar 31, 2023 | - | |
| 10-K | Mar 31, 2023 | Dec 31, 2022 | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
GLSI SEC filings: frequently asked questions
Are GLSI insiders buying or selling?
In the last 90 days, Greenwich LifeSciences, Inc. (GLSI) officers, directors and 10% owners reported 5 open-market purchases worth $97,003 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold GLSI stock?
As of June 30, 2026, the largest Greenwich LifeSciences, Inc. (GLSI) holders among the 13F filers tracked by SignalX were BlackRock ($11.4 million), Vanguard Capital Management LLC ($6.5 million), State Street Corp ($3.4 million), Vanguard Portfolio Management LLC ($1.9 million), Northern Trust ($1.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the latest GLSI SEC filings?
Greenwich LifeSciences, Inc. (GLSI) filed its latest 10-K annual report on June 1, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on December 18, 2025 and a Form 4 insider filing on July 30, 2026.
What is GLSI's SEC CIK number?
Greenwich LifeSciences, Inc. (GLSI)'s SEC Central Index Key (CIK) is 1799788. EDGAR lists every GLSI filing under that number.
Ask anything about GLSI
The research agent reads GLSI's filings, financials, insider trades and 13F holders, then answers with sources.